Ceramide C6-d7

CAT: 0804-HY-19542SSize: 500 μg (2.47 mM x 500 μL in Methanol)Dry Ice: NoHazardous: No
CAT#:0804-HY-19542SSize:500 μg (2.47 mM x 500 μL in Methanol)
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Ceramide C6-d7 is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells[1][2][3].
CAS Number
[2692624-22-7]
UNSPSC
12352211
Hazard Statement
H225, H301+H311+H331, H370
Target
Apoptosis; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Others
Field of Research
Cancer
Concentration
2.47 mM * 500 μL in Methanol
Purity
99.0
Solubility
10 mM in DMSO
Smiles
OC[C@@H]([C@@H](/C=C/CCCCCCCCCCC([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])O)NC(CCCCC)=O
Molecular Formula
C24H40D7NO3
Molecular Weight
404.68
Precautions
H225, H301+H311+H331, H370
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Qiu L, et al. C6-ceramide induces salivary adenoid cystic carcinoma cell apoptosis via IP3R-activated UPR and UPR-independent pathways. Biochem Biophys Res Commun. 2020;525 (4) :997-1003.|[3]Liu L, et al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020;18 (1) :298. Published 2020 Aug 3.
Shipping Conditions
Blue Ice
Storage Conditions
Solution, -20°C, 2 years
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported